Helix BioPharma Corporation is a Canada-based biopharmaceutical company focused on cancer therapy. It is developing products for the treatment and prevention of cancer based on its technologies. The Company’s product development initiatives have focused on its L-DOS47 and Topical Interferon Alpha-2b new drug candidates. It operates through the biopharmaceuticals segment. The Company’s most advanced product clinically is its Topical Interferon Alpha-2b as a treatment for certain skin/mucosal lesions caused by HPV infections. Its DOS47 is a patented oncology platform technology that offers a new and potentially revolutionary approach to the debilitation and destruction of cancer cells. Its L-DOS47 is a new drug in development that offers an approach to the debilitation and destruction of non-small cell lung cancer cells.